Immunogenicity of therapeutic proteins: Clinical implications and future prospects

Clinical Therapeutics

Volumn 24, Issue 11, 2002, Pages 1720-1740

  Schellekens, Huub ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antibodies; Cytokines; Hormones; Immunology; Interferons; Recombinant proteins

Indexed keywords

ALEMTUZUMAB; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALTEPLASE; BETA1A INTERFERON; CHORIONIC GONADOTROPIN; DACLIZUMAB; GONADORELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON BETA SERINE; INTERLEUKIN 2; INTERLEUKIN 3; MILODISTIM; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT CYTOKINE; RECOMBINANT DNA; RECOMBINANT ENZYME; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GROWTH FACTOR; RECOMBINANT HORMONE; RECOMBINANT HUMAN INSULIN; RECOMBINANT PROTEIN; RECOMBINANT RECEPTOR; RHDNASE; SALCATONIN; STAPHYLOKINASE; STREPTOKINASE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ALLERGIC REACTION; ANEMIA; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; AUTOIMMUNITY; BIOASSAY; BLOOD CLOT LYSIS; BREAST CANCER; CLINICAL TRIAL; CONJUGATE; CONTAMINATION; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG ADMINISTRATION ROUTE; EXON; GENETICS; GROWTH HORMONE DEFICIENCY; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERCALCEMIA; HYPOGONADOTROPIC HYPOGONADISM; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN ALLERGY; LEUKEMIA; MALE INFERTILITY; MULTIPLE SCLEROSIS; NEUTROPENIA; NONHUMAN; OXIDATION; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PRIMATE; PROTEIN AGGREGATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PURE RED CELL ANEMIA; RECOMBINANT DNA TECHNOLOGY; REVIEW; RHEUMATOID ARTHRITIS; SITE DIRECTED MUTAGENESIS; STORAGE; SUBSTITUTION THERAPY; SUPPLEMENTATION; TRANSGENIC MOUSE; TREATMENT INDICATION; TURNER SYNDROME;

EID: 0036861899     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80075-3     Document Type: Article

References (88)

1. Myhr KM, Ross C, Nyland HI, et al. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive. Neurology. 2000;55:1569-1572.
2. Oberg K, Alm G, Magnusson A, et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: Development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst. 1989;81:531-535.
3. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19:376-388.
4. Gelfand EW. Antibody-directed therapy: Past, present, and future. J Allergy Clin Immunol. 2001;108:S111-S116.
5. Milner RDG, Flodh H. Immunological Aspects of Human Growth Hormone: Proceedings of a Workshop, London, 12 November 1985. Oxford: Medical Education Services; 1986.
6. Hurter P, Kuhnau J. Avidity and binding capacity of bovine and porcine insulin binding antibodies in childhood diabetes [in German]. Monatsschr Kinderheilkd. 1970;118:250-252.
7. Rosenschein U, Lenz R, Radnay J, et al. Streptokinase immunogenicity in thrombolytic therapy for acute myocardial infarction. Isr J Med Sci. 1991;27:541-545.
8. Vanderschueren SM, Stassen JM, Collen D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb Haemost. 1994;72:297-301.
9. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002;1:457-462.
10. Ryff JC, Schellekens H. Immunogenicity of rDNA-derived pharmaceuticals. Trends Pharmacol Sci. 2002;23:254-256.
11. Porter S. Human immune response to recombinant human proteins. J Pharm Sci. 2001;90:1-11.
12. Ryff JC. Clinical investigation of the immunogenicity of interferon-alpha 2a. J Interferon Cytokine Res. 1997;17(Suppl 1):S29-S33.
13. Perini P, Facchinetti A, Bulian P, et al. Interferon-beta (INF-beta) antibodies in interferon-betal a- and interferon-betal b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw. 2001;12:56-61.
14. Gribben JG, Devereux S, Thomas NS, et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet. 1990;335:434-437.
15. Antonelli G, Giannelli G, Currenti M, et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy. Clin Exp Immunol. 1996;104:384-387.
16. Figlin RA, Itri LM. Anti-interferon antibodies: A perspective. Semin Hematol. 1988;25(3 Suppl 3):9-15.
17. Grauer A, Ziegler R, Raue F. Clinical significance of antibodies against calcitonin. Exp Clin Endocrinol Diabetes. 1995;103:345-351.
18. Jacquemin MG, Saint-Remy JM. Factor VIII immunogenicity. Haemophilia. 1998;4:552-557.
19. Giannelli G, Antonelli G, Fera G, et al. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C. Clin Exp Immunol. 1994;97:4-9.
20. McSweeney EN, Giles FJ, Worman CP, et al. Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia. Br J Haematol. 1993;85:77-83.
21. Lok AS, Lai CL, Leung EK. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology. 1990;12:1266-1270.
22. Fossa SD, Lehne G, Gunderson R, et al. Recombinant interferon alpha-2A combined with prednisone in metastatic renal-cell carcinoma: Treatment results, serum interferon levels and the development of antibodies. Int J Cancer. 1992;50:868-870.
23. Bonetti P, Diodati G, Drago C, et al. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha. J Hepatol. 1994;20:416-420.
24. Prümmer O. Treatment-induced antibodies to interleukin-2. Biotherapy. 1997;10:15-24.
25. Blumenfeld Z, Frisch L, Conn PM. Gonadotropin-releasing hormone (GnRH) antibodies formation in hypogonadotropic azoospermic men treated with pulsatile GnRH - Diagnosis and possible alternative treatment. Fertil Steril. 1988;50:622-629.
26. Claustrat B, David L, Faure A, Francois R. Development of anti-human chorionic gonadotropin antibodies in patients with hypogonadotropic hypogonadism. A study of four patients. J Clin Endocrinol Metab. 1983;57:1041-1047.
27. Ragnhammar P, Wadhwa M. Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy. Med Oncol. 1996;13:161-166.
28. Venekamp WJ, van der Hooft JC, Jacobsen L, van Schaik CL. Immunogenicity of bovine, porcine and semisynthetic human insulin. Neth J Med. 1985;28(Suppl 1):57-58.
29. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care. 1993;16(Suppl 3):155-165.
30. Fineberg SE, Galloway JA, Fineberg NS, et al. Immunogenicity of recombinant DNA human insulin. Diabetologia. 1983;25:465-469.
31. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469-475.
32. Casadevall N. N Engl J Med. 2002;346:1585. Letter.
33. Briet E, Peters M. The incidence of inhibitors in hemophilia A and the induction of immune tolerance. Adv Exp Med Biol. 2001;489:89-97.
34. Eisenberg JD, Aitken ML, Dorkin HL, et al. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr. 1997;131(1 pt 1):118-124.
35. Zang YC, Yang D, Hong J, et al. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology. 2000;55:397-404.
36. Bukowski RM, Olencki T, Gunn H, et al. Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: Hematological, immunological, and pharmacodynamic findings. Clin Cancer Res. 1996;2:347-357.
37. Miller LL, Korn EL, Stevens DS, et al. Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood. 1999;93:3250-3258.
38. Ragnhammar P, Friesen HJ, Frodin JE, et al. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmuno-compromised patients. Blood. 1994;84:4078-4087.
39. Laricchia-Robbio L, Moscato S, Genua A, et al. Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum. J Cell Physiol. 1997;173:219-226.
40. Husson RN, Chung Y, Mordenti J, et al. Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection. J Pediatr. 1992;121:627-633.
41. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology. 1999;53:457-465.
42. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med. 2002;346:1584-1586.
43. Donovan AJG. EPREX (Epoetin Alfa) - Pure Red-Cell Aplasia (PRCA, Erythroblastopenia): Amended Advice on Route of Administration and Reminder about Storage and Administration. High Wycome, UK: Ortho Biotech; 2002.
44. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst. 1993;10:307-377.
45. Fakharzadeh SS, Kazazian HH Jr. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost. 2000;26:167-171.
46. Prescott R, Nakai H, Saenko EL, et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood. 1997;89:3663-3671.
47. Reeves WG, Gelsthorpe K, Van der Minne P, et al. HLA phenotype and insulin antibody production. Clin Exp Immunol. 1984;57:443-448.
48. Van Haeften TW. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care. 1989;12:641-648.
49. Palleroni AV, Aglione A, Labow M, et al. Interferon immunogenicity: Preclinical evaluation of interferon-alpha 2a. J Interferon Cytokine Res. 1997;17(Suppl 1):S23-S27.
50. Antonelli G, Dianzani F. Development of antibodies to interferon beta in patients: Technical and biological aspects. Eur Cytokine Netw. 1999;10:413-422.
51. The European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Proprietary Medicinal Products (CPMP 3097/02). Note for guidance on comparability of medicinal products containing biotechnology-derived proteins as drug substance. Annex on non-clinical and clinical considerations. 2002. (http://www. emea.eu.int)
52. Chance RE, Root MA, Galloway JA. The immunogenicity of insulin preparations. Acta Endocrinol Suppl (Copenh). 1976;205:185-198.
53. Lawley WJ, Fletcher S, Squire IB, et al. T-cell recognition of discrete regions of the thrombolytic drug streptokinase. Clin Sci (Lond). 2000;99:239-246.
54. Chang TY. Towards a quantitative model of immunogenicity: Counting pathways in sequence space. J Theor Biol. 2000;206:255-278.
55. Fierlbeck G, Schreiner T, Schaber B, et al. Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta. Cancer Immunol Immunother. 1994;39:263-268.
56. Preece M. Human pituitary growth hormone and Creutzfeldt-Jakob disease. Horm Res. 1993;39:95-98.
57. Peces R, de la Torre M, Alcazar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med. 1996;335:523-524.
58. Kontsek P, Liptakova H, Kontsekova E. Immunogenicity of interferon-alpha 2 in therapy: Structural and physiological aspects. Acta Virol. 1999;43:63-70.
59. Melian EB, Plosker GL. Interferon alfacon-1: A review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs. 2001;61:1661-1691.
60. Girard F, Gourmelen M. Clinical experience with Somatonorm. Acta Paediatr Scand Suppl. 1986;325:29-32.
61. Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol. 2000;48:706-712.
62. Levy F, Muff R, Dotti-Sigrist S, et al. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease. J Clin Endocrinol Metab. 1988;67:541-545.
63. Cross AH, Antel JP. Antibodies to beta-interferons in multiple sclerosis: Can we neutralize the controversy? Neurology. 1998;50:1206-1208.
64. Hochuli E. Interferon immunogenicity: Technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res. 1997;17 (Suppl 1):S15-S21.
65. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al. A sudden increase in factor VIII inhibitor development in multi-transfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood. 1993;81:2180-2186.
66. Casato M, Lagana B, Antonelli G, et al. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood. 1991;78:3142-3147.
67. von Wussow P, Pralle H, Hochkeppel HK, et al. Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia. Blood. 1991;78:38-43.
68. Roffi L, Mels GC, Antonelli G, et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: Prevalence, etiology, and management. Hepatology. 1995;21:645-649
69. von Wussow P, Hartmann F, Freund M, et al. Leucocyte-derived interferon-alpha in patients with antibodies to recombinant IFN-alpha 2b. Lancet. 1988;1:882-883.
70. Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology. 1998;51:1698-1702.
71. Bertolotto A, Malucchi S, Milano E, et al. Interferon beta neutralizing antibodies in multiple sclerosis: Neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology. 2000;48:95-100.
72. DiMichele D, Kroner B. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: The North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis. Haematologica. 2000;85(10 Suppl):40-42; discussion 42-44.
73. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia - Principal results from the international registry. Report of the factor VIII and IX subcommittee. Thromb Haemost. 1994;72:155-158.
74. Adair F, Ozanne D. The immunogenicity of therapeutic proteins. BioPharm. 2002;15:30-36.
75. Wierda D, Smith HW, Zwickl CM. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology. 2001;158:71-74.
76. Zwickl CM, Cocke KS, Tamura RN, et al. Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys. Fundam Appl Toxicol. 1991;16:275-287.
77. Stewart TA, Hollingshead PG, Pitts SL, et al. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol Biol Med. 1989;6:275-281.
78. Ottesen JL, Nilsson P, Jami J, et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia. 1994;37:1178-1185.
79. Shiffman ML. Pegylated interferons: What role will they play in the treatment of chronic hepatitis C? Curr Gastroenterol Rep. 2001;3:30-37.
80. Perry CM, Jarvis B. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C. BioDrugs. 2002;16:213-217.
81. Wang YS, Youngster S, Grace M, et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev. 2002;54:547-570.
82. Wan M, Wang Y, Rabideau S, et al. An enzyme-linked immunosorbent assay for host cell protein contaminants in recombinant PEGylated staphylokinase mutant SY161. J Pharm Biomed Anal. 2002;28:953-963.
83. Kolkman JA, Stemmer WP. Directed evolution of proteins by exon shuffling. Nat Biotechnol. 2001;19:423-428.
84. Pavlinkova G, Colcher D, Booth BJ, et al. Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs. Int J Cancer. 2001;94:717-726.
85. Klingbeil C, Hsu DH. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use. Toxicol Pathol. 1999;27:1-3.
86. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999;26 (4 Suppl 12):78-83.
87. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody, rhuMAb-E25 Study Group. N Engl J Med. 1999;341:1966-1973.
88. Matteson EL, Yocum DE, St Clair EW, et al. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum. 1995;38:1187-1193.